Abstract T-cell acute lymphoblastic leukaemia (T-ALL) is a challenging malignancy with a high relapse rate attributed to drug resistance. Tetrandrine (TET), a bisbenzylisoquinoline alkaloid extracted from a Chinese herb, is a potential anti-cancer and anti-leukaemic drug. In this study we investigated the mechanisms of TET resistance in T-ALL cells in vitro. Among the four T-ALL cell lines tested, Jurkat and CEM cells exhibited the lowest and highest resistance to TET with IC 50 values at 24 h of 4.31±0.12 and 16.53±3.32 μmol/L, respectively. When treated with TET, the activity of transcription factor activator protein 1 (AP-1) was significantly decreased in Jurkat cells but nearly constant in CEM cells. To avoid cell-specific variation in drug resistance and transcription factor activities, we established a TET-R Jurkat subclone with the estimated IC 50 value of 10.90±.92 μmol/L by exposing the cells to increasing concentrations of TET. Interestingly, when treated with TET, TET-R Jurkat cells exhibited enhanced AP-1 and NF-κB activity, along with upregulation of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling pathways, whereas the expression of P-gp was not altered. Selective inhibition of JNK but not ERK suppressed AP-1 activity and TET resistance in TET-R Jurkat cells and in CEM cells. These results demonstrate that Jurkat cells acquire TET resistance through activation of the JNK/AP-1 pathway but not through P-gp expression. The JNK/AP-1 pathway may be a potential therapeutic target in relapsed T-ALL.
Introduction
T-cell acute lymphoblastic leukaemia (T-ALL), a neoplastic monoclonal proliferation of abnormal immature T lymphocytes in bone marrow, is an aggressive malignancy that frequently manifests with multiple organ involvement and is associated with poor treatment outcomes [1] [2] [3] . Drug resistance, either intrinsic or acquired, is important in treatment failure of T-ALL chemotherapy [4] . Unravelling the mechanisms of drug resistance could help overcome treatment failure and improve prognosis.
Tetrandrine (TET), a bisbenzylisoquinoline alkaloid extracted from Han-Fang-Chi (Stephania tetrandra S Moore), is a well-known calcium channel blocker commonly used as # These authors contributed equally to this work. * To whom correspondence should be addressed. an anti-hypertensive and anti-arrhythmic drug in modern China [5] . Several lines of evidence demonstrate the pleiotropic properties of TET, such as anti-inflammatory, immunosuppressive and anti-rheumatic effects [6, 7] . Furthermore, growing evidence has revealed the anti-cancer effects of TET against diverse cancer cell lines, including leukaemia, lymphoma, neuroblastoma and glioma cell lines, as well as breast, lung, liver and colon cancer cells [8] [9] [10] [11] . In a clinical trial, TET, in combination with traditional chemotherapy drugs, had encouraging anti-leukaemic effects and was well tolerated [12] . These findings suggest that TET is a potentially novel anti-leukaemic agent and adjuvant therapy for T-ALL. However, the mechanism of drug resistance to TET in T-ALL has not been investigated.
The activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB) families of transcription factors are now understood to be important in human cancer and are validated targets in cancer drug discovery [13] . Our previous study demonstrated that TET cytotoxicity (at therapeutic concentrations) is mediated through an apoptotic mechanism in leukaemia/lymphoma cell lines; this cytotoxic effect was relatively exclusive to T-ALL and peripheral blood T-cells, compared with B-cell lymphoma and monocytic leukaemia cell lines [14] . These findings suggest that differential activities of transcription factors, especially AP-1 and NF-κB, might be involved in the varying drug resistance/sensitivity to TET in T-ALL.
In this study, we examined the viability of four T-ALL cell lines treated with TET and compared AP-1 and NF-κB activities between cell lines with distinct TET resistance. A TETresistant subclone of Jurkat cells was established to investigate the role of the MAPK/AP-1 pathway in T-ALL drug resistance against TET. Our results demonstrate that Jurkat cells might acquire resistance against TET through activation of the JNK/ AP-1 pathway but not through modulation of P-glycoprotein (P-gp) expression, the most widely studied multidrug resistance (MDR) protein.
Materials and methods
Reagents and preparation of TET Preparation of TET has been described previously [15] . Briefly, TET powder (purity >98%; Yichang Pharmaceutical Company, China) was dissolved in 0.1 mol/L HCl at a stock concentration of 50 mmol/L and stored at -20 °C until use. For each experiment, the stock solution was further diluted in culture medium to the desired concentrations. MAPK inhibitors, including extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) inhibitors (PD98059 and SP600125, respectively), and anti-P-gp mouse monoclonal antibody (mAb) were purchased from Darmstadt (Germany). Antibodies against phospho (p)-p44/42 ERK (Thr202/Tyr204), p-SAPK/JNK (Thr183/Thr185) kinase and p-p38 (Thr180/ Tyr182) were obtained from Cell Signaling (Danvers, MA, USA). Total p44/42 ERK, SAPK/JNK, p38 and USF-2 were recognized by antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-actin mAb was obtained from Chemicon (Temecula, CA, USA). Unless otherwise specified, other reagents were purchased from Sigma-Aldrich Chemical Company (St Louis, MO, USA).
Cells and culture media
All cell lines were purchased from the Bioresource Collection and Research Center (BCRC, Taiwan, China). Human T-cell lines (Jurkat, CEM, MOLT-4 and SUP-T1) and the monocytic cell line THP-1 were grown in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS; Biological Industries), 2 mmol/L L-glutamine, 2 g/L sodium bicarbonate and antibiotics (100 unit/mL of penicillin and 100 μg/mL streptomycin). The culture media for Jurkat, THP-1 and SUP-T1 cells also contained 10 mmol/L HEPES and 1 mmol/L sodium pyruvate. In addition, the culture medium for SUP-T1 cells was supplemented with 4.5 g/L D-(+)-glucose. A549 cells (type II human lung alveolar epithelial cell carcinoma) were grown in Ham's F12K medium containing 2 mmol/L L-glutamine, 1.5 g/L sodium bicarbonate, 10% FBS and antibiotics. HepG2 cells (a human hepatocellular carcinoma cell line) were grown in minimum essential medium with Earle's salt, supplemented with 10% FBS, 2 mmol/L L-glutamine, 1.5 g/L sodium bicarbonate, 0.1 mmol/L non-essential amino acids and antibiotics. SW480 cells were grown in Leibovitz's L-15 medium supplemented with 10% FBS, 2 mmol/L L-glutamine and antibiotics. Jurkat, CEM, MOLT-4, SupT1, THP-1, A549 and HepG2 cells were cultured at 37 °C in a humidified incubator with 5% CO 2 and maintained in log phase. SW480 cells were grown at 37 °C in a humidified incubator without CO 2 . Cells (3×10 5 cell/mL) were treated with different concentrations of TET for various incubation periods, as indicated in the figures and legends. All culture media and supplements were obtained from Invitrogen (Carlsbad, CA, USA), unless otherwise indicated.
Cell viability and cytotoxicity assays
A trypan blue exclusion assay was used to measure the effect of TET on the viability of T-ALL cells, as described previously [14] . Briefly, after treatment at the indicated dose and duration, the cells were harvested, stained with trypan blue (0.5% solution) and counted using a haemocytometer.
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the cytotoxic effect of TET on cells. In brief, cells were seeded in a 96-well plate and treated with TET for 24 h. Then, the cells were washed once with phosphate-buffered saline (PBS; pH 7.4), and 200 μL of MTT (USB/Amersham Life Science, Cleveland, OH, USA) solution (1 mg/mL in PBS buffer) was added to each well. After incubation at 37 °C for 4-6 h, the supernatant was carefully removed, and the purple formazan precipitate that was converted from yellow MTT salt by mitochondrial dehydrogenases in viable cells was dissolved in 200 μL of dimethyl sulfoxide. Optical density was measured with an ELISA reader (Tecan, Grodig, Australia) at a wavelength of 590 nm. Cell viability is presented as the percentage of medium-treated cells, which was set as 100% viable. IC 50 values (the compound concentration resulting in 50% inhibition of cell viability) after 24 h of TET treatment were calculated using Microsoft Excel software.
The cytotoxicity of TET was estimated using a cytotoxicity detection kit (LDH; Roche, Indianapolis, IN, USA) according to the manufacturer's protocol. After treatment as indicated, 100 μL of supernatant from each well was collected, transferred into a new 96-well plate, and mixed with the kit reagents. Optical density at 490 nm, indicating lactate dehydrogenase activity, was measured with an ELISA reader (Tecan). Percent cytotoxicity was calculated as follows: (sample value−medium control)/(high control−medium control)×100. An equal number of cells treated with 1% Triton X-100 was used as the high control.
Development of a TET-resistant Jurkat cell line
The Jurkat cell line was maintained by serial passage in the presence of incrementally increasing doses of TET, starting from 0.5 μmol/L and finally reaching 5 μmol/L. Dead www.chinaphar.com Liou JT et al Acta Pharmacologica Sinica cells were removed by Ficoll gradient centrifugation, and the TET concentration in the medium was increased as cell lines achieved 80% viability. Over a period of 6-9 months, a Jurkat subclone resistant to 5 μmol/L TET was established and labelled the TET-resistant (TET-R) Jurkat cell line. The parental Jurkat cells, which were more sensitive to TET cytotoxicity, were labelled TET-sensitive (TET-S) Jurkat cells. Cells were counted for 3 consecutive days using a trypan blue assay, and cell doubling time was calculated using the equation T d (h)=T×[log 2/(log N−log N 0 )], where T d is the doubling time, T is the time in the logarithmic proliferative phase (h), N is the cell number at the end of the logarithmic proliferative phase and N 0 is the cell number at the beginning of the logarithmic proliferative phase.
Flow cytometry
Flow cytometry was performed to evaluate apoptotic cell death and investigate the cell cycle distribution, as described in our previous report [14] . In brief, after treatment with 5 μmol/L TET for 24 h, TET-S and TET-R Jurkat cells were washed twice with PBS and fixed in ice-cold 70% ethanol for 2 h. Then, the cells were stained with a solution containing 20 μg/mL propidium iodide (PI), 0.2 mg/mL DNase-free RNase A and 0.1% Tritox-100 for 30 min at room temperature. Subsequently, cells were analysed by flow cytometry using a FACScan system (BD Biosciences, San Jose, CA, USA). The proportions of cells in all phases (G 0 /G 1 , S and G 2 ) were quantified. Cell cycle was analysed with ModFit LT™ software (Verity Software House Inc, Topsham, ME, USA), and the percentage of cells in each phase was determined.
Annexin-V and 7-amino-actinomycin D (7-AAD) staining assay The Annexin-V and 7-AAD staining assay was performed according to the manufacturer's protocol (PE Annexin-V Apoptosis Detection Kit I, BD Pharmingen TM ). Cells were washed twice with cold PBS and then phycoerythrin (PE) Annexin-V and 7-AAD were added to the binding buffer. The reaction proceeded in the dark for 15 min at room temperature. The cells were then analysed and quantified using flow cytometry.
Nuclear extract preparation Nuclear extracts were prepared and quantified using a Bradford assay (Biorad), as previously described [16] . In brief, after collection and a single wash with PBS solution, cells (3×10 glycerol, 1 mmol/L DTT, 0.5 mmol/L PMSF and 1 μg/mL aprotinin) and incubated at 4 °C for 30 min with occasional vigorous vortexing, followed by centrifugation of the mixtures at 15 000 revolutions per minute for 20 min. The supernatants were used as nuclear extracts.
Electrophoretic mobility shift assay (EMSA) EMSAs were performed as detailed in our previous report [17] .
Oligonucleotides with NF-κB or AP-1 response elements (NF-κB binding site: 5′-AGTTGAGGGGACTTTCCCAGGC-3′; AP-1 binding site: 5′-CGCTTGATGAGTCAGCCGGAA-3′) were radiolabelled with [γ-
32 P]-ATP using T4 kinase (Promega, Madison, WI, USA) and used as DNA probes. The NF-κB DNA probe consisted of synthetic polynucleotides with a sequence equivalent to the IL-2 promoter NF-κB response element. Nuclear extract (4 μg) was incubated with radiolabelled AP-1 or NF-κB probes in EMSA-binding buffer containing 10 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCl, 0.5 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L MgCl 2 , 4% glycerol and 0.5 μg poly(dI-dC). The binding reaction proceeded at room temperature for 20 min. DNA-binding specificity was determined by a competing assay in which the nuclear extract was incubated with a 100-fold molar excess of unlabelled AP-1 or NF-κB oligonucleotide for 10 min before the addition of the radiolabelled probes. Unlabelled non-specific oligonucleotides from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were also included as a negative control. The final reaction mixtures were separated by electrophoresis on a 6.6% nondenaturing polyacrylamide gel at 250 V for 70 min. After electrophoresis, gels were dried and subjected to radiography.
Transient transfection and luciferase reporter assays
Transfections were performed using TransFast (Promega, Madison, WI, USA) as a transfection reagent according to the manufacturer's recommendations and our previous report, with some modification [17] . In brief, TET-S and TET-R Jurkat cells were seeded overnight at a concentration of 1×10 6 cells/mL onto 6-well culture plates and then transfected with 2 μg of the reporter plasmid pAP-1-luciferase (TGACTAA) 7 or pNF-κB-luciferase (TGGGGACTTTCCGC) 5 (Stratagene, La Jolla, CA, USA) in the presence of 1 ng of the internal control plasmid pTK-Renilla-luciferase (Promega, Madison, WI, USA) in 500 μL of serum-and antibiotic-free transfection medium with 6 μL of TransFast. The subunit of NF-κB studied in the luciferase experiment was the p65/p50 heterodimer. Cells in each well were refreshed with 5 mL of RPMI-1640 medium supplemented with 10% FBS 1 h after transfection and then further incubated for another 48 h. After treatment with 5 μmol/L TET, total cell lysates were collected and firefly luciferase activities were analysed using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), with Renilla luciferase activity as an internal control. All experiments were performed at least 3 times.
Western blotting analysis
Western blotting was performed using an enhanced chemi-luminescence kit (Amersham Bioscience, UK), as described previously [14, 17] . Briefly, after treatment at the indicated concentration and duration of TET, the cells were washed once with PBS, pelleted and resuspended in 100 μL of RIPA buffer [150 mmol/L NaCl, 50 mmol/L Tris-HCL (pH 7.5), 1 mmol/L EDTA, 1% (v/v) NP-40, 0.25% deoxycholate containing proteinase inhibitors (1 mmol/L PMSF, 1 μg/mL aprotinin, 1 μg/mL leupeptin and 1 μg/mL pepstatin) and phosphatase inhibitor (1 mmol/L sodium orthovanadate; Sigma; 1 mmol/L sodium fluoride; Merck)]. After periodic vortexing, the mixtures were subjected to centrifugation at 14 000 revolutions per minute for 20 min at 4 °C, and the supernatants containing the total cell lysates were collected. Equal amounts of protein samples were resolved by 8% or 10% SDS-PAGE at 120 V and transferred to nitrocellulose membranes. For immunoblotting, the nitrocellulose membrane was incubated with 5% non-fat milk dissolved in TBS-T [10 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl and 0.05% Tween-20] for 2 h and then blotted with primary antibodies against individual proteins for 2 h at room temperature. After triple washing with TBS-T, the membranes were incubated with secondary antibody conjugated with horseradish peroxidase (HRP; Chemicon, Temecula, CA, USA) at a dilution of 1:3000 for 1 h at room temperature. The membranes were then incubated with enhanced chemiluminescence substrate (Amersham Bioscience, UK) and exposed to BioMax Light Film (Kodak).
Immunoprecipitation kinase assay Cells were lysed in 100 μL of buffer C (20 mmol/L HEPES, 420 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 0.2 mmol/L EDTA, 25% glycerol, 1 mmol/L DTT, 1 mmol/L PMSF and 1 μg/mL aprotinin), and 50 μg of protein was incubated with 2 μL of antiphospho-p44/p42 MAPK antibody in 1 mL of incubation buffer for 4-6 h, mixed with 40 μL of protein-A Sepharose CL-4B beads (GE Health Care, Montreal, Canada) at 4 °C, and rotated overnight. After a few washes, the immunoprecipitates were collected for further kinase assays. Kinase reactions were performed in a solution containing 10.5 μL ddH20, 20 μL of 2× kinase buffer, 3 μL of 2 mg/mL ERK substrate (myelin basic protein, MBP), 6 μL of unlabelled ATP and 0.5 μL of [γ-
32 P]-ATP at room temperature for 30 min. The proteins were then separated by SDS-PAGE (15% acrylamide gel), followed by autoradiography to visualize MBP phosphorylation.
Statistical analysis
All experiments were performed independently at least 3 times, except where otherwise stated in the figure legends. IC 50 values represent the mean±SD (n=3). Paired conditions were compared using Student's t-test, and differences were considered significant at a P value of <0.05.
Results

TET cytotoxicity varied in diverse cancer, T-ALL cell lines and a TET-R Jurkat subclone
The viability of various human cancer cell lines against different concentrations of TET (0-100 μmol/L) were determined using MTT assays, and the IC 50 of TET at 24 h was measured accordingly (Table 1) . We found that cell lines derived from haematologic malignancies, including CEM, MOLT-4, SUP-T1 and Jurkat cells (ie, the 4 T-ALL cell lines), as well as THP-1 cells (an acute monocytic leukaemia cell line), were more sensitive to TET cytotoxicity than were other carcinoma cell lines (namely, A549, HepG2 and SW480 cells). Among the 4 T-ALL cell lines, the IC 50 of TET was highest against CEM cells (16.53±3.32 μmol/L) and lowest against Jurkat cells (4.31±0.12 μmol/L), as was the case in our previous study [14] . After treatment with TET for 24 h, the cell viability of CEM and Jurkat cells diverged greatly at both 5 μmol/L and 10 μmol/L (Figure 1A) . The time course for the cytotoxic effect of TET on both cell lines was further studied at these two concentrations. After treatment with 5 μmol/L TET, almost 90% of the CEM cells survived at 24 h, but less than 40% of the Jurkat cells survived at 18 h ( Figure 1B) . After exposure to 10 μmol/L TET, nearly 80% of the CEM cells survived at 24 h, but less than 40% of the Jurkat cells survived at 12 h ( Figure 1C ). Because the sensitivity to TET cytotoxicity between CEM and Jurkat cells differed the most, these two cell lines were used in subsequent experiments to examine the mechanism of resistance to TET in T-ALL cells.
To avoid cell-specific variation in drug resistance and transcription factor activities, a TET-R Jurkat subclone was established as mentioned in the material and methods. The of the cell cycle distribution with ModFit software revealed an increase in apoptosis of TET-S Jurkat cells treated with 5 μmol/L TET ( Figure 2D ), which was also confirmed using another approach, ie, by staining cells with Annexin-V and 7-AAD ( Figure 2E ).
AP-1 activity was suppressed by TET in TET-S Jurkat cells
To investigate the roles of AP-1 and NF-κB in the mechanism of drug resistance to TET, the DNA-binding activity of AP-1 and NF-κB in the nuclear extracts of TET-S Jurkat cells treated with 10 μmol/L TET for 2, 6, 12, 18 and 24 h was evaluated using EMSAs. The results showed that AP-1 activity significantly decreased in Jurkat cells as the exposure time increased following treatment ( Figure 3A) , whereas NF-κB activity seemed to markedly increase at 12 h and then return to nearbasal levels at 24 h ( Figure 3B ). These EMSA results suggested a correlation between AP-1 activity and resistance to TET in T-ALL cells.
AP-1 activity increased in TET-R Jurkat cells EMSA analyses showed higher DNA-binding activities of AP-1 and NF-κB in TET-R Jurkat cells ( Figure 4A , lane 3) than that in control (TET-S) Jurkat cells ( Figure 4A, lane 1) . A supershift assay using specific NF-κB subunits showed that pre-incubation with anti-p50 monoclonal antibodies resulted in two supershifted bands, clearly demonstrating the involvement of the NF-κB p50 subunit ( Figure 4B, lane 7) . We also treated TET-S Jurkat cells with 5 μmol/L TET, the same con- Figure 4A , lane 1). These findings further highlighted the significance of AP-1 activation in drug resistance against TET ( Figure 4A, lanes 2 and 4) . In addition, both AP-1 and NF-κB activities constitutively increased in TET-R Jurkat cells ( Figure 4A, lane 3) . The transcriptional activities of AP-1 and NF-κB analysed using dual-luciferase reporter assays showed results similar to those of the EMSA analyses ( Figure 4C ). These results suggested that enhanced AP-1 DNA-binding activity and subsequent transcriptional activity contributed to drug resistance and protected TET-R Jurkat cells against TET toxicity. However, treatment with TET reduced AP-1 reporter activities but had no effects on NF-κB reporter activities in TET-S Jurkat cells ( Figure 4C, lane 2) . Total protein levels of p65, p50 and c-Fos, but not c-Jun, decreased in TET-S Jurkat cells treated with TET ( Figure 4D ). The discrepancies between p65/ p50 protein expression and NF-κB reporter activities might be due to compensatory mechanisms from the activation of other alternative NF-κB pathways, such as those associated with the p52 and RelB subunits [18] . The results from reporter assays suggested that AP-1, but not NF-κB signalling, may be involved in the mechanism of resistance to TET in T-ALL cells.
P-gp was not expressed in TET-R Jurkat and CEM cells
The expression of P-gp, an important cell-membrane-associated protein mediating multidrug resistance in cancer, was analysed using Western blotting. As shown in Figure 4E , neither CEM nor TET-R Jurkat cells expressed P-gp in comparison to SW480 cells that constitutively express P-gp. This finding implied that another mechanism rather than P-gp overexpression contributed to the higher TET resistance of CEM and TET-R Jurkat cells.
JNK and ERK, but not p38, MAPKs were activated in TET-R Jurkat cells
To investigate the upstream mechanism of AP-1 activation, MAPKs were analysed by Western blotting of cell lysate. As shown in Figure 4F , after treatment with 5 μmol/L TET for 24 h, the expression of phosphorylated JNK (p-JNK) and phosphorylated ERK (p-ERK) increased in TET-R Jurkat cells but was suppressed in TET-S Jurkat cells. Expression of phosphorylated p38 (p-p38) was not detected in either cell type. These results suggested that the signal for AP-1 activation in TET-R Jurkat cells might be mediated by overexpression of p-JNK and p-ERK.
JNK/AP-1 activation contributed to drug resistance in TET-R Jurkat cells
To verify the contribution of the MAPK pathway to AP-1 activation and consequent resistance to TET, cells were also treated with specific MAPK inhibitors for 24 h, after which AP-1 DNA-binding activity, cell viability and cytotoxicity were measured using EMSA, MTT and LDH assays, respectively. As shown in Figure 5A , selective inhibition of JNK by 20 μmol/L SP600125 markedly suppressed the downstream AP-1 activity and cell viability (to approximately 60% of control levels) of TET-R Jurkat cells treated with 5 μmol/L TET for 24 h ( Figure 5A, lane 2) . Moreover, 20 μmol/L SP600125 also noticeably suppressed AP-1 activity in TET-R Jurkat cells in the absence of TET treatment, but cell viability and LDH release were not significantly affected ( Figure 5A, lane 5) . Nevertheless, the AP-1 activity and cell viability of TET-R Jurkat cells were not significantly affected by selective ERK inhibition with PD98059 for 24 h, although LDH release was moderately increased ( Figure 5B, lane 2) . The effect of 40 μmol/L PD98059 on selective ERK inhibition was confirmed by an immunoprecipitation kinase assay ( Figure 5C ). To further were incubated in 6-well plates overnight and treated with 5 μmol/L TET for 24 h, after which they were sorted and fixed with alcohol.
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Discussion
Aberrant cellular signalling pathways and dysregulated signalling networks are important in tumourigenesis and drug resistance of T-cell malignancies and hence serve as good targets for leukaemia therapy [19] . In this study, we analysed T-ALL cell lines with varying resistances to TET and experimentally induced TET resistance in a Jurkat subclone. We found that TET resistance in TET-R Jurkat cells was attributable to activation of AP-1 activity but not to expression of the multidrug transporter P-gp. AP-1 activation and TET resistance were apparently mediated by JNK activation, as both AP-1 activity and cell survival were suppressed by selective inhibition of JNK (but not ERK) in TET-R cells.
T-cell lymphoblastic leukaemias usually originate from T-cell progenitors and are characterized by limited differentiation and incessant proliferation. These leukaemic cells are regarded as the malignant equivalents of their normal counterparts but have stopped at specific maturation stages during differentiation [20] . CEM, MOLT-4, SUP-T1 and Jurkat cells are T-ALL cell lines frequently used in immunologic and molecular studies, either as a model of T-cell malignancy or as a substitute for normal T-cells. However, immunophenotyping and T-cell receptor studies have shown that these cell lines correlate with various differentiation stages of normal human thymocytes [21] . CEM belongs to the pre-T-cell stage, MOLT-4 and SUP-T1 to the cortical T-cell stage, and Jurkat (Table 1) : T-ALL cells with a more immature phenotype were more resistant to TET cytotoxicity. The MOLT-4 T-ALL cell line is derived from the same patient as the MOLT-3 cell line but was established from cells taken from this patient during relapse after multidrug chemotherapy [22] . The SUP-T1 T-lymphoblastic lymphoma cell line was originally derived from the pleural effusion of an 8-year-old boy during relapse [23] . In the present study, TET displayed marked cytotoxicity in the MOLT-4 and SUP-T1 cell lines, even more so than in the CEM cells. These findings further demonstrated the potential of TET, both as an anti-cancer agent and against relapsed or refractory T-cell malignancy. Nevertheless, resistance to TET may eventually evolve by certain mechanism(s) in T-ALL cells after exposure to TET in clinical chemotherapy, given the properties of evolution and clonal expansion of cancers [24] . Many studies have found that transcription factors are important in drug resistance and are good targets for cancer therapy, but these investigations mostly focused on NF-κB [25] . The roles of AP-1 in oncogenesis and tumour suppression are contradictory because the actions of AP-1 are complex and highly context-specific [26] . Limited evidence suggests an association of AP-1 activity with resistance of leukaemia to some chemotherapeutic agents, such as etoposide [27] , glucocorti- 
(E)
The expression of P-glycoprotein (P-gp) in cells with different levels of resistance to TET after treatment with or without TET for 24 h was evaluated by Western blotting. β-Actin was used as an internal control for equal loading. SW480 cells, which constitutively express P-gp, served as a positive control.
www.nature.com/aps Liou JT et al Acta Pharmacologica Sinica coid [28] and vitamin D [29] , not involving a multidrug resistance mechanism. In the present study, a Jurkat subclone with resistance to 5 μmol/L TET was established to investigate the possible mechanism of TET resistance at the transcriptional level.
Western blotting, EMSA and luciferase reporter assays were used to evaluate total protein expression of specific subunits of AP-1 and NF-κB, DNA-binding activities and DNA-transcriptional activities, respectively, in nuclear extracts of cells with different TET resistance. Our results revealed the contribution of AP-1 and possible NF-κB activation to TET resistance in T-ALL cells. There might be some concern about whether the EMSA results in Figure 2B are relevant if most Jurkat cells were killed soon after exposure to 10 μmol/L TET ( Figure 1C ). However, when using a nuclear extraction protocol, it is likely that nuclear proteins are extracted from residual viable cells. In addition, equal amounts of nuclear extracts quantified by the Bradford assay were subjected to EMSA. Moreover, the NF-κB activity was not reduced, in contrast to AP-1 activities. Instead, it increased at 6 to 12 h after exposure to 10 μmol/L TET. This suggests that AP-1 and NF-κB have different roles in the mechanisms of cell survival and TET resistance in T-ALL. As shown in Figure 4C , treatment with TET had no effects on luciferase reporter activities in TET-S Jurkat cells, suggesting that NF-κB signalling might not be involved in the mechanism regarding resistance against TET in T-ALL cells. AP-1 activation is mainly mediated by upstream MAPK intracellular signalling cascades consisting of 3 major MAPKs, namely, JNK, ERK and p38 [30, 31] . The MAPK pathway is important in controlling cell differentiation, proliferation and survival, and its mutation is associated with drug resistance in some malignancies [32] , but its role in T-ALL is unclear. Phosphorylation of AP-1 components by kinases in the MAPK pathway, such as JNK, ERK and p38 MAPKs, correlates closely with functional activation of AP-1 complexes. Interestingly, as Figure 4D shows, not only AP-1 but also upstream p-JNK and p-ERK were clearly activated in TET-R Jurkat cells treated with TET. AP-1 activity and drug resistance to TET in TET-R Jurkat and CEM cells were markedly attenuated by the specific JNK inhibitor SP600125 ( Figure 5A and 6) but were unaffected by the specific ERK inhibitor PD98059 ( Figure 5B ). These results demonstrate a correlation between the JNK/ AP-1 pathway and TET resistance in T-ALL cells. Activation of the JNK pathway in T-ALL indirectly reduced the sensitivity of T-ALL to other chemotherapeutic agents. In SUP-T1 cells, lack of expression of the Bcl-2-interacting mediator of cell death (Bim) protein, a BH3-only member of the Bcl-2 family of proteins, confers resistance to etoposide-induced apoptosis. Constitutive activation of the JNK pathway in SUP-T1 cells promotes phosphorylation and degradation of Bim via the proteasome, thereby contributing to etoposide resistance. Suppression of JNK by SP600125 restores the Bim level and abolishes resistance of SUP-T1 cells to etoposide [33] . Another study of human T-ALL cell lines showed that JNK inhibition by SP600125 and small interfering RNA led to cell cycle arrest and apoptosis and increased sensitivity to Fas-mediated apoptosis, whereas constitutive JNK activity in T-ALL cells resulted in accelerated cell cycle progression and resistance to Fas-mediated apoptosis. These past and present results shed light on the mechanism of TET resistance and further suggest the potential of JNK as a therapeutic target in the treatment of T-ALL. P-gp is encoded by the multidrug resistance protein-1 (MDR1) gene, which is also known as the ATP-binding cassette transporter B1 (ABCB1) gene. P-gp is a key efflux transporter leading to multidrug resistance and chemotherapy failure. Experimentally inducing drug resistance in cultured leukaemic cell lines by gradually increasing drug concentration yielded insights into the underlying mechanisms of treatment failure. A previous study showed that Jurkat cells express very little MDR1 and that the intrinsic drug resistance of Jurkat cells does not appear to involve MDR1 [34] . However, MDR1/P-gp expression was induced and MDR was acquired in several experimental drug-resistant T-ALL cell lines, including Jurkat cells, after exposure to incremental concentrations of various chemotherapeutic agents [35] [36] [37] . Unlike other chemotherapeutic agents, TET and its derivatives clearly show the effects of reversing MDR in a human T-ALL cell line and carcinoma cell lines mediated by P-gp [38, 39] . A TET-R Jurkat subclone obtained by serial passage in the presence of increasing TET concentrations did not express P-gp in our studyg ( Figure 4C ). This suggests that chemoresistance is both celland drug-specific. We hypothesize that the anti-MDR activity of TET remains even after drug resistance against the anticancer effect of TET develops.
This study has some limitations. Although TET-R Jurkat cells were successfully selected and clearly had enhanced AP-1 activity, the IC 50 of TET was only a few times greater than that of TET-S Jurkat cells at 24 h. However, the IC 50 of TET against TET-S Jurkat cells would have been much lower if cell viability had been determined after 5 d of culture, as in some previous studies [35] . Apart from AP-1 expression, a difference in proliferation rate between TET-R and TET-S Jurkat cells was unexpectedly discovered. The proliferation rate of TET-R Jurkat cells with higher AP-1 activity was slower than that of the TET-S clone. It remains to be determined whether specific activation of the JNK/AP-1 pathway or merely AP-1 overexpression reduces the proliferation rate and confers TET resistance in Jurkat T-ALL cells.
In conclusion, to our knowledge this is the first study to examine the mechanism of TET resistance in T-ALL cells at the transcriptional level. The findings confirmed that TET resistance in T-ALL cells is P-gp-independent and suggest that this drug resistance is associated with activation of the JNK/AP-1 pathway. Our study provides a comprehensive mechanistic approach for cancer chemotherapeutic resistance, which could be applied to the treatment of patients with refractory T-ALL in the near feature.
